Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AcelRx Pharmaceuticals, Inc. (ACRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.2400+0.0500 (+2.28%)
At close: 04:00PM EST
2.2700 +0.03 (+1.34%)
After hours: 06:31PM EST
Advertisement

AcelRx Pharmaceuticals, Inc.

25821 Industrial Boulevard
Suite 400
Hayward, CA 94545
United States
650 216 3500
https://www.acelrx.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Mr. Vincent J. AngottiCEO & Director915.29kN/A1968
Dr. Pamela Pierce Palmer M.D., Ph.D.Co-Founder, Chief Medical Officer & Director682kN/A1963
Mr. Raffi Mark AsadorianChief Financial Officer623.1kN/A1969
Mr. Lawrence G. HamelConsultantN/AN/A1952
Mr. Anil N. DasuChief Engineering OfficerN/AN/A1963
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Corporate Governance

AcelRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement